30th Jan 2020 14:21
(Alliance News) - Creo Medical Group PLC said it performed in line with expectations in 2019 and expects "significant growth" in orders for its Speedboat gastrointestinal medical product.
The medical devices maker said Speedboat generated initial revenue in 2019
On Speedboat, Creo said: "It is in the final stages of agreeing a third-party manufacturing contract to facilitate larger scale production. The company has already validated the first batches of products from the third-party manufacturer and is confident of the high quality and consistency of production."
Elsewhere, the company said it is working towards gaining regulatory approvals for a further four devices.
Creo added: "Technical files are now complete and, with revised arrangements with the company's notified body, all four products will be CE marked in Europe simultaneously on receipt of the company's new EC certificate, which is expected in the near term.
A CE mark is a certification needed for products sold within the European Economic Area.
Creo shares were 2.0% lower at 171.50 pence each in London on Thursday afternoon.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Creo Medical